Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
09:19pm, Thursday, 14'th Mar 2024
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
04:01pm, Thursday, 14'th Mar 2024
SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
09:30am, Thursday, 07'th Mar 2024
The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Co
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
09:30am, Thursday, 29'th Feb 2024
SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
09:30am, Thursday, 01'st Feb 2024
SALT LAKE CITY , Feb. 1, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
09:30am, Wednesday, 27'th Dec 2023
The Company's Emergency Use Authorization submission is for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home. The menu of tests in development for the pla
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
07:59pm, Thursday, 09'th Nov 2023
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer B
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development
09:30am, Thursday, 02'nd Nov 2023
Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , Nov. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasda
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023
09:30am, Tuesday, 31'st Oct 2023
SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast
09:30am, Thursday, 26'th Oct 2023
SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25
09:30am, Monday, 23'rd Oct 2023
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Sustainable Infrastructure Dividend ETF Distributions
09:18am, Monday, 23'rd Oct 2023
TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Middlefield Sustainable Infrastructure Dividend ETF (TSX: MINF) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2023 wil
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
06:16pm, Thursday, 10'th Aug 2023
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.10 per share a year ago.
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
09:30am, Thursday, 27'th Jul 2023
SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
10:33pm, Thursday, 11'th May 2023
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian B
